Endo International PLC (NASDAQ:ENDP) gapped down prior to trading on Wednesday following insider selling activity. The stock had previously closed at $17.51, but opened at $17.84. Endo International PLC shares last traded at $17.39, with a volume of 2,015,057 shares trading hands.

Specifically, Director Roger H. Kimmel sold 14,000 shares of the stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $17.38, for a total value of $243,320.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.70% of the stock is currently owned by company insiders.

ENDP has been the subject of a number of recent research reports. JPMorgan Chase & Co. reissued an “overweight” rating and set a $40.00 price objective on shares of Endo International PLC in a research note on Tuesday, July 26th. Vetr raised shares of Endo International PLC from a “buy” rating to a “strong-buy” rating and set a $19.14 price objective for the company in a research note on Monday, August 1st. Morgan Stanley set a $15.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Friday, August 5th. BMO Capital Markets reissued a “hold” rating and set a $22.00 price objective on shares of Endo International PLC in a research note on Tuesday, August 9th. Finally, Leerink Swann reissued a “hold” rating and set a $22.00 price objective (down from $23.00) on shares of Endo International PLC in a research note on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Endo International PLC currently has an average rating of “Buy” and a consensus target price of $31.63.

The stock’s market cap is $3.80 billion. The company has a 50-day moving average price of $19.05 and a 200 day moving average price of $18.75.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.20. The firm had revenue of $894.30 million for the quarter, compared to analyst estimates of $862.47 million. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. The company’s revenue for the quarter was up 18.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 EPS. Equities research analysts expect that Endo International PLC will post $4.60 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENDP. Heartland Advisors Inc. bought a new position in Endo International PLC during the second quarter valued at $15,627,000. State Street Corp raised its position in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock valued at $147,021,000 after buying an additional 805,101 shares in the last quarter. Schneider Capital Management Corp bought a new position in Endo International PLC during the second quarter valued at $6,941,000. Quantitative Investment Management LLC raised its position in Endo International PLC by 166.2% in the second quarter. Quantitative Investment Management LLC now owns 654,800 shares of the company’s stock valued at $10,208,000 after buying an additional 408,800 shares in the last quarter. Finally, Alps Advisors Inc. bought a new position in Endo International PLC during the second quarter valued at $4,877,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.